HB5256 (the “340B ACCESS Act”) proposes a wide-ranging overhaul of the 340B drug discount program. It narrows which prescriptions qualify for 340B pricing by defining a ‘‘patient’’ with in-person encounter requirements (and strict limits on telehealth), tightens hospital off-campus ‘‘child site’’ eligibility, restricts which nonhospital entities and subgrantees may use 340B drugs, imposes limits on contract pharmacy arrangements (including a 5‑pharmacy cap for some hospitals), and creates new reporting, audit, and civil‑penalty regimes.
The bill also mandates patient affordability rules (sliding‑fee caps for low‑ and moderate‑income patients), explicit limits on third‑party administrator and contract pharmacy fees, and a federally contracted claims data clearinghouse to detect duplicate discounts and reconcile manufacturer rebates.
Those changes reallocate program oversight and operational work to HHS and to covered entities. The proposal aims to eliminate improper duplicate Medicaid rebates and increase transparency about how 340B savings are used, but it also creates new registration, recordkeeping, auditing, and IT obligations — plus civil monetary penalties and required repayments to manufacturers where eligibility or procedural rules are not met.
If enacted, covered entities, pharmacies, state Medicaid programs, manufacturers and PBMs will all face concrete compliance, reporting and financial impacts.
At a Glance
What It Does
The bill tightens the statutory ‘‘patient’’ standard (time-limited in-person visit, provider relationship, care‑coordination exceptions), redefines which nonhospital entities qualify (including a $1 billion revenue affiliate threshold), restricts and prescribes rules for contract and mail‑order pharmacies, requires granular claim‑level reporting and a federally contracted clearinghouse to detect duplicate discounts, and imposes sliding‑fee caps and fee limits plus civil penalties and repayment obligations.
Who It Affects
Disproportionate‑share and other 340B hospitals (including off‑campus child sites), federally funded clinics and their subgrantees, contract and entity pharmacies (including mail‑order), drug manufacturers (rebate exposure), state Medicaid programs and Medicare contractors, and pharmacy benefit managers and third‑party administrators.
Why It Matters
The bill shifts program enforcement from a largely voluntary architecture toward mandatory registration, real‑time data exchange and federal audits — altering the economic returns hospitals and clinics realize from 340B and creating direct financial exposure (repayments, civil penalties) for compliance failures. Providers must upgrade billing, contracting and data flows; manufacturers and payors gain tools to prevent duplicate rebates.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
HB5256 rewrites many of the operational rules that have governed 340B for two decades. It starts by tightening the statutory ‘‘patient’’ definition: a prescription qualifies for 340B pricing only when the drug is tied to a covered entity provider’s service, the provider has an ongoing relationship with the patient and creates auditable records, and — in most cases — the provider has seen the patient in person within a specified look‑back period (12 months for most hospitals and 24 months for nonhospital entities).
The bill limits telehealth‑originated prescriptions unless an in‑person exam occurred in the prior six months (with a narrow eligibility exception tied to Social Security benefit status), and it bars prescriptions from non‑covered‑entity providers except where a documented ‘‘care coordination’’ sequence exists and specific contractual and documentation conditions are met.
The measure redefines which nonhospital entities may act as 340B participants by creating a ‘‘specified nonhospital covered entity’’ category (including affiliates) for organizations with average annual revenues over $1 billion (three‑year average, CPI‑adjusted). It tightens subgrantee rules: nonhospital grantees must be nonprofit or public, must have enforceable written agreements with any subgrantee, must register subgrantee sites, and must be directly liable for subgrantee compliance; subgrantees that receive in‑kind contributions must document ongoing eligibility and, in certain circumstances, meet Medicaid concentration tests.Contract pharmacy arrangements receive detailed limits and conditions.
Covered entities must register every contract pharmacy and certify compliance; certain hospitals (free‑standing cancer hospitals, rural referral centers and hospitals with local government contracts) may use no more than five contract pharmacies. The bill sets a service‑area standard based on Census Public Use Microdata Areas, restricts when mail‑order may be used, requires written contracts with enforceable compliance obligations, and imposes escalating monetary penalties, required corrective action plans, and removal from the program for repeated pharmacy violations.To detect and prevent duplicate discounts and improper rebate submissions, HB5256 requires claim‑level data submission to a federal clearinghouse.
Covered entities (and dispensing pharmacies) must submit detailed standardized elements (NDCs, NPIs, prescription numbers, dates, quantities, payor identifiers, 340B modifiers and a care‑coordination indicator) within tight timelines; Medicaid agencies, Medicare contractors, Medicare Advantage and Part D sponsors must likewise feed claim data. The clearinghouse is tasked with identifying duplicate rebate/discount filings, notifying affected parties within days, facilitating refunds to manufacturers, and supporting exclusion of 340B purchased units from inflation‑rebate calculations.
HHS will contract with an independent third party to run that clearinghouse under strict confidentiality and security rules.Transparency and financial‑use reporting are central. The Secretary must publish annual, machine‑readable reports showing counts of 340B‑dispensed patients by payer category, margins on 340B drugs and how those margins are used (UDS‑style categories such as medical care, sliding fee discounts, outreach, pharmaceuticals).
Hospitals that rely on state or local contracts to qualify must make those contracts public, meet minimum charity‑care and Medicaid‑revenue thresholds for off‑campus ‘‘child sites’’ or be deregistered, and demonstrate that their community benefit obligations (charity care) at least match 340B margin over a lookback period or face deregistration and repayment obligations. Finally, the bill caps permissible remuneration to TPAs and contract pharmacies (flat fees only; contract pharmacy per‑dispense fees capped at 125% of the average per‑prescription dispensing fee) and creates civil penalties for a broad set of noncompliance scenarios.
The Five Things You Need to Know
The bill defines ‘‘patient’’ to require a covered‑entity provider‑to‑patient relationship with auditable records and generally an in‑person visit within 12 months (hospitals) or 24 months (most nonhospital entities) before a prescription becomes 340B‑eligible.
A nonhospital covered entity is ‘‘specified’’ and faces extra rules if it or an affiliate averages over $1 billion in annual operating revenue (three‑year average, CPI‑adjusted).
Certain hospitals (free‑standing cancer hospitals, some rural referral centers, and those qualifying via state/local contracts) are limited to no more than five contract pharmacies under 340B; other entities must register each contract pharmacy and certify compliance.
The Secretary must contract a third‑party clearinghouse (within one year) to ingest claim‑level 340B and payor data, identify duplicate discounts or rebate submissions, notify parties within days, and support manufacturer refunds and program reconciliations.
Covered entities must cap eligible patients’ out‑of‑pocket for each 340B dispense: $0 for families below federal poverty, up to $35 (under 200% FPL) and up to $50 (200%+ FPL), with adjusted thresholds for inflation.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Rewrites 'patient' and defines 'specified nonhospital covered entity'
The bill inserts a detailed statutory patient test into 340B: qualifying drugs must be tied to a covered‑entity provider’s service, dispensed on‑site or at registered pharmacies, and supported by auditable records. It adds concrete telehealth limits (generally requires a prior in‑person exam) and a narrowly drawn care‑coordination pathway for specialist referrals. It also creates a new ‘‘specified nonhospital covered entity’’ label – triggered by affiliation with a hospital or a $1 billion revenue threshold – which subjects those entities to heightened limitations and oversight. Practically, these definitions will drive who can claim 340B discounts and create a new gating function for program eligibility.
Mandates HHS rulemaking and audit powers to prevent duplicate Medicaid rebates
HHS must promulgate regulations within a year to prescribe the methodologies states, covered entities and contract pharmacies use to identify and bill 340B drugs so Medicaid rebate requests do not duplicate 340B discounts. The Secretary gains explicit audit authority to inspect how covered entities use 340B margins and requires records retention for enforcement. For compliance officers this means new interaction with state Medicaid programs and potential clawbacks where rebates were improperly claimed.
Sets a strict provider‑based test and community‑need thresholds for off‑campus child sites
To register an off‑campus outpatient facility as a child site, a hospital must show provider‑based Medicare cost report inclusion (or certified equivalent), wholly owned status, Medicare provider‑based determinations, non‑drug‑only outpatient services, adherence to hospital charity‑care policies, and local shortage‑area designation tied to HRSA scoring as of Dec 1, 2024. Private nonprofit hospitals relying on state/local contracts must show the child site complies with contract obligations. The bill adds numerical tests for charity‑care and Medicaid/outpatient revenue shares that child sites must meet; failure triggers deregistration, required audits, repayments to manufacturers, and civil penalties. These mechanics convert prior softer guidance into enforceable statutory thresholds.
Comprehensive registration, contract, service‑area and penalty regime for contract pharmacies
Contract pharmacies must be registered in the federal 340B identification system (including NPI), and covered entities must certify compliance procedures that address duplicate discounts, resale prohibitions, and patient affordability. The bill restricts certain hospital types to five contract pharmacies, defines service areas using Public Use Microdata Areas, and tightly limits mail‑order use to specific entity categories and geographies. Written agreements must include enforceable compliance obligations and be submitted to HHS; pharmacies face escalating liability: repayment of manufacturer discounts, increasing civil penalties, required corrective action plans, removal from the program and multi‑year disqualification for repeat violations.
Sliding‑fee rules and point‑of‑sale caps for patients receiving 340B drugs
Hospitals with 340B eligibility must adopt sliding fee scales that cap per‑prescription out‑of‑pocket at $0 for patients below poverty, up to $35 for those under 200% FPL, and up to $50 for those at or above 200% FPL (CPI‑adjusted). Contract pharmacies dispensing on behalf of covered entities must apply these discounts and are subject to penalties for noncompliance. For many safety‑net patients this creates an enforceable limit on cost sharing; for covered entities it creates an operational obligation to verify income/insurance and implement point‑of‑sale discounts.
Mandates claim modifiers and standardized, rapid claim‑level submission to a clearinghouse
Claims for 340B‑purchased drugs must include an established 340B modifier (Medicare Part B modifier or NCPDP Submission Clarification Code) and a non‑340B modifier when drugs were not purchased under 340B. Covered entities must furnish detailed claim‑level elements (NDC, NPIs, prescription and adjudication dates, payor identifiers, 340B indicator, wholesaler invoice, etc.) to a clearinghouse within 45 days (or shorter if the Secretary requires). Records must meet HIPAA security standards and follow field definitions set by the clearinghouse. Nonreporting triggers daily civil monetary penalties.
Annual public reporting, margin disclosure, and stricter hospital eligibility
The Secretary will publish annual machine‑readable reports listing 340B patient counts by payer category, margins on 340B drugs and categorical uses of margin (UDS‑style lines such as sliding fee discounts, outreach, pharmaceuticals). Hospitals qualifying via contracts must submit those contracts and demonstrate minimum charity‑care contributions or be deregistered. The bill also tightens criteria for sole community and rural hospital categories. These provisions convert internal accounting items into public compliance data that manufacturers, payors, and researchers can analyze.
Creates a federally contracted clearinghouse tasked with reconciling 340B claims
HHS must contract with an independent third party to operate a clearinghouse that ingests covered‑entity, Medicaid, Medicare and Part D claims and rebate file data. The clearinghouse will detect duplicate Medicaid discounts, identify claims that should be excluded from inflation‑rebate calculations, notify state agencies, manufacturers and covered entities within days of findings, and support manufacturer refunds and subsequent recoveries from responsible parties. The clearinghouse is subject to strict confidentiality and HIPAA‑level security and may not be affiliated with covered entities.
Caps on third‑party admin and contract pharmacy remuneration
TPAs may receive only flat per‑service fees (not fees tied to drug price/discount). Contract pharmacies’ per‑dispense fees must be flat and cannot exceed 125% of the pharmacy’s average per‑prescription dispensing fee (measured across payors). Noncompliant TPAs or pharmacies face civil penalties equal to ten times the unlawful payment amount. The rule forces most compensation into fixed‑fee models and forbids percentage‑based fee structures linked to 340B savings.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Manufacturers: gain a centralized clearinghouse and statutory tools to detect and stop duplicate Medicaid rebate claims and duplicate 340B discounts, plus clearer pathways to obtain repayments where misuse is found.
- State Medicaid programs: receive a federal mechanism (and regulatory guidance) to reconcile 340B purchases with rebate submissions and reduce inadvertent duplicate rebate payments.
- Low‑income patients served at covered hospitals and qualifying nonhospital entities: receive statutory caps on out‑of‑pocket payments for 340B drugs (including a $0 cap for those below the poverty line), improving affordability at point of dispense.
- HHS and OIG: receive explicit statutory authority to audit use of 340B margins, review contracts, impose civil monetary penalties, and operate or contract the clearinghouse — strengthening federal oversight tools.
- Smaller safety‑net providers that meet eligibility and reporting requirements and that use 340B savings for charity care and community services: obtain greater legitimacy and public visibility through mandated margin‑use reporting.
Who Bears the Cost
- Covered entities (hospitals and nonhospital grantees): face increased administrative and compliance costs for registration, audits, recordkeeping, income verifications, sliding fee implementation, reporting to the clearinghouse, and possible repayments and civil penalties if eligibility or documentation standards are not met.
- Contract pharmacies and TPAs: must restructure compensation into flat fees, register and enter enforceable contracts, submit claim‑level data, and assume potential high civil penalties and program removal for repeated violations — creating commercial risk and likely higher operating costs.
- State Medicaid programs and Medicare contractors: must establish rapid data feeds to the clearinghouse and implement procedures to correct rebate requests; states may need systems changes and increased staffing to respond to clearinghouse notices.
- Drug manufacturers: although given tools to identify duplicate discounts, manufacturers could face administrative burdens responding to clearinghouse notices and processing refund claims; manufacturers also assume short‑term cash flow risk pending repayment reconciliations.
- Pharmacy networks and PBMs: contract restrictions and prohibitions on certain plan actions (per the bill’s nondiscrimination provisions) could require renegotiation of networks and reimbursement terms and may reduce PBM leverage over dispensing and audit practices.
Key Issues
The Core Tension
The central dilemma is reconciling program integrity with program viability: stricter definitions, registration tests, audit powers and data reconciliation reduce improper discounts and protect manufacturers and payors, but they also shrink and complicate the revenue stream that safety‑net providers rely on to fund charity care and wraparound services — a trade‑off between financial accountability and the practical ability of underserved communities to access affordable medicines and related services.
HB5256 pursues two goals at once: (1) tighten program integrity and eliminate duplicate Medicaid rebates, and (2) protect patient affordability while increasing transparency about margin use. Those goals collide in implementation.
For example, the patient‑eligibility and in‑person requirements will reduce the volume of prescriptions that qualify for 340B pricing — lowering program revenues used by safety‑net providers — while the rule‑driven registration and child‑site tests create immediate deregisration and repayment risk where historical registrations don’t cleanly map to the bill’s new thresholds. The clearinghouse is the bill’s keystone: if it works with secure, timely, standardized feeds from Medicaid, Medicare, PDPs, MA plans, covered entities and pharmacies, it can detect true duplicate claims.
If data quality, governance, or legal limits hamper the feeds, the clearinghouse could generate false positives or leave gaps, which would create disputes and expensive appeals.
Operational tension also arises around contract pharmacies and TPAs. The bill forces flat‑fee economics and caps per‑dispense fees; pharmacies that depended on percentage or margin‑based arrangements will face immediate renegotiation pressures or closed doors to the program.
The bill’s escalating penalties — large repayments to manufacturers, per‑claim civil fines, and program removal for repeat violations — change commercial calculus and could push some pharmacies and TPAs to refuse 340B business, reducing patient access in some areas. Lastly, the public margin‑use reporting requirement aims at transparency but will be technically challenging: mapping internal accounting (margin, allowable program costs, third‑party fees) into standardized public fields risks inconsistent interpretations and disputes about what counts as ‘‘program‑related’’ expenses versus general operating costs.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.